Literature DB >> 24384773

Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.

P R A Buijs1, C H J van Eijck1, L J Hofland2, R A M Fouchier3, B G van den Hoogen3.   

Abstract

Newcastle disease virus (NDV) is a naturally occurring oncolytic virus with clinically proven efficacy against several human tumor types. Selective replication in and killing of tumor cells by NDV is thought to occur because of differences in innate immune responses between normal and tumor cells. In our effort to develop oncolytic virotherapy with NDV for patients with pancreatic cancer, we evaluated the responses to NDV infection and interferon (IFN) treatment of 11 different established human pancreatic adenocarcinoma cell lines (HPACs). Here we show that all HPACs were susceptible to NDV. However, this NDV infection resulted in different replication kinetics and cytotoxic effects. Better replication resulted in more cytotoxicity. No correlation was observed between defects in the IFN pathways and NDV replication or NDV-induced cytotoxicity. IFN production by HPACs after NDV infection differed substantially. Pretreatment of HPACs with IFN resulted in diminished NDV replication and decreased the cytotoxic effects in most HPACs. These findings suggest that not all HPACs have functional defects in the innate immune pathways, possibly resulting in resistance to oncolytic virus treatment. These data support the rationale for designing recombinant oncolytic NDVs with optimized virulence that should likely contain an antagonist of the IFN pathways.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24384773     DOI: 10.1038/cgt.2013.78

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  43 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

3.  Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells.

Authors:  Yoshito Tomimaru; Hidetoshi Eguchi; Hiroshi Wada; Akira Tomokuni; Shogo Kobayashi; Shigeru Marubashi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Masaki Mori; Yuichiro Doki; Hiroaki Nagano
Journal:  Int J Oncol       Date:  2011-02-23       Impact factor: 5.650

4.  Newcastle disease virus selectively kills human tumor cells.

Authors:  K W Reichard; R M Lorence; C J Cascino; M E Peeples; R J Walter; M B Fernando; H M Reyes; J A Greager
Journal:  J Surg Res       Date:  1992-05       Impact factor: 2.192

5.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Type I interferons as radiosensitisers for pancreatic cancer.

Authors:  Marjolein J M Morak; Peter M van Koetsveld; Roland Kanaar; Leo J Hofland; Casper H J van Eijck
Journal:  Eur J Cancer       Date:  2011-04-07       Impact factor: 9.162

7.  Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro.

Authors:  Robert J Walter; Bashar M Attar; Asad Rafiq; Megan Delimata; Sooraj Tejaswi
Journal:  JOP       Date:  2012-09-10

8.  Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.

Authors:  M Janke; B Peeters; O de Leeuw; R Moorman; A Arnold; P Fournier; V Schirrmacher
Journal:  Gene Ther       Date:  2007-10-04       Impact factor: 5.250

9.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.

Authors:  Dmitriy Zamarin; Luis Martínez-Sobrido; Kaitlyn Kelly; Mena Mansour; Gang Sheng; Adam Vigil; Adolfo García-Sastre; Peter Palese; Yuman Fong
Journal:  Mol Ther       Date:  2009-02-10       Impact factor: 11.454

10.  Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions.

Authors:  T Ohta; T Terada; T Nagakawa; H Tajima; H Itoh; L Fonseca; I Miyazaki
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  23 in total

Review 1.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

3.  Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.

Authors:  P R A Buijs; G van Amerongen; S van Nieuwkoop; T M Bestebroer; P R W A van Run; T Kuiken; R A M Fouchier; C H J van Eijck; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

Review 4.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

5.  In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.

Authors:  L M E Berghauser Pont; R K Balvers; J J Kloezeman; M O Nowicki; W van den Bossche; A Kremer; H Wakimoto; B G van den Hoogen; S Leenstra; C M F Dirven; E A Chiocca; S E Lawler; M L M Lamfers
Journal:  Gene Ther       Date:  2015-07-21       Impact factor: 5.250

Review 6.  Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy.

Authors:  Fang Huang; Chuanjing Dai; Youni Zhang; Yuqi Zhao; Yigang Wang; Guoqing Ru
Journal:  Front Mol Biosci       Date:  2022-07-04

7.  Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters.

Authors:  D Jochmans; S van Nieuwkoop; S L Smits; J Neyts; R A M Fouchier; B G van den Hoogen
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.

Authors:  Samantha B Kasloff; Matteo S Pizzuto; Micol Silic-Benussi; Silvia Pavone; Vincenzo Ciminale; Ilaria Capua
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

9.  Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers.

Authors:  Yuan Lin; Haipeng Zhang; Jiankai Liang; Kai Li; Wenbo Zhu; Liwu Fu; Fang Wang; Xiaoke Zheng; Huijuan Shi; Sihan Wu; Xiao Xiao; Lijun Chen; Lipeng Tang; Min Yan; Xiaoxiao Yang; Yaqian Tan; Pengxin Qiu; Yijun Huang; Wei Yin; Xinwen Su; Haiyan Hu; Jun Hu; Guangmei Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

Review 10.  Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.